Serial No. : Filed :

Page : 3 of 28

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## Listing of Claims:

1. (original) A compound of formula (I), 
$$(R^2R^3)-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}-A^{18}-A^{19}-A^{20}-A^{21}-A^{22}-A^{23}-A^{24}-A^{25}-A^{26}-A^{27}-A^{28}-A^{29}-A^{30}-A^{31}-A^{32}-A^{33}-A^{34}-A^{35}-A^{36}-A^{37}-A^{38}-A^{39}-R^1 (SEQ ID NO:412),$$
 (I)

wherein

A<sup>7</sup> is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A<sup>8</sup> is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A<sup>9</sup> is Glu, N-Me-Glu, N-Me-Asp or Asp;

 $A^{10}$  is Gly, Acc,  $\beta$ -Ala or Aib;

A<sup>11</sup> is Thr or Ser;

A<sup>12</sup> is Phe, Acc, Aic, Aib, 3-Pal, 4- Pal, β-Nal, Cha, Trp or X<sup>1</sup>-Phe;

A<sup>13</sup> is Thr or Ser;

A<sup>14</sup> is Ser or Aib;

A<sup>15</sup> is Asp or Glu;

A<sup>16</sup> is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;

A<sup>17</sup> is Ser or Thr;

A<sup>18</sup> is Ser or Thr;

A<sup>19</sup> is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X<sup>1</sup>-Phe;

A<sup>20</sup> is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X<sup>1</sup>-Phe;

A<sup>21</sup> is Glu or Asp;

 $A^{22}$  is Gly, Acc,  $\beta$ -Ala, Glu or Aib;

Applicant: Zheng Xin Dong

Serial No.:

Filed

Page : 4 of 28

A<sup>23</sup> is Gln, Asp, Asn or Glu;

A<sup>24</sup> is Ala, Aib, Val, Abu, Tle or Acc;

 $A^{25}$  is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O) or NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);

Attorney's Docket No.: 00537-186003

 $A^{26}$  is Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O) or NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);  $A^{27}$  is Glu Asp, Leu, Aib or Lys;

A<sup>28</sup> is Phe, Pal, β- Nal, X<sup>1</sup>-Phe, Aic, Acc, Aib, Cha or Trp;

A<sup>29</sup> is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;

A<sup>30</sup> is Ala, Aib or Acc;

 $A^{31}$  is Trp,  $\beta$ -Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;

A<sup>32</sup> is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X<sup>1</sup>-Phe or Ala;

A<sup>33</sup> is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X<sup>1</sup>-Phe;

 $A^{34}$  is Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O) or NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);

 $A^{35}$  is Gly,  $\beta$ -Ala, D-Ala, Gaba, Ava, NH-(CH<sub>2</sub>)<sub>m</sub>-C(O), Aib, Acc or a D-amino acid;

 $A^{36}$  is L-or D-Arg, D-or L-Lys, D-or L-hArg, D-or L-Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O) or deleted;

 $A^{37}$  is Gly,  $\beta$ -Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, NH-(CH<sub>2</sub>)<sub>m</sub>-C(O), HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), a D-amino acid, or deleted;

A<sup>38</sup> is D-or L-Lys, D-or L-Arg, D-or L-hArg, D-or L-Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O), Ava, Ado, Aec or deleted;

 $A^{39}$  is D-or L-Lys, D-or L-Arg, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), Ava, Ado, or Aec;

 $X^{1}$  for each occurrence is independently selected from the group consisting of ( $C_{1}$ - $C_{6}$ )alkyl, OH and halo;

 $R^1$  is OH, NH<sub>2</sub>, (C<sub>1</sub>-C<sub>30</sub>) alkoxy, or NH-X<sup>2</sup>-CH<sub>2</sub>-Z<sup>0</sup>, wherein  $X^2$  is a (C<sub>1</sub>-C<sub>12</sub>) hydrocarbon moiety, and  $Z^0$  is H, OH, CO<sub>2</sub>H or CONH<sub>2</sub>;  $X^4$ —N N—(CH<sub>2</sub>), -CH<sub>3</sub>

 $X^3$  is

Serial No.:

Filed

Page : 5 of 28

or -C(O)-NHR<sup>12</sup>, wherein  $X^4$  is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH<sub>2</sub>-, and wherein f is , independently for each occurrence, an integer from 1 to 29 inclusive; each of  $R^2$  and  $R^3$  is independently selected from the group consisting of H,  $(C_1-C_{30})$ alkyl,  $(C_2-C_{30})$ alkenyl, phenyl $(C_1-C_{30})$ alkyl, naphthyl $(C_1-C_{30})$ alkyl, hydroxy $(C_1-C_{30})$ alkyl, hydroxyphenyl $(C_1-C_{30})$ alkyl, and hydroxynaphthyl $(C_1-C_{30})$ alkyl; or one of  $R^2$  and

 $R^3$  is  $(CH_3)_2$ -N-C=N(CH<sub>3</sub>)<sub>2</sub>,  $(C_1$ -C<sub>30</sub>)acyl,  $(C_1$ -C<sub>30</sub>)alkylsulfonyl,  $C(O)X^5$ ,

$$Y(CH_2)_r - N$$
 $N - (CH_2)_q SO_2 - Y(CH_2)_r - N$ 
 $N - (CH_2)_q - CO_2 - O_1 - O_2 - O_2 - O_3 - O_$ 

; wherein Y is H, OH or NH<sub>2</sub>; r is 0 to 4; q is 0 to 4; and  $X^5$  is  $(C_1-C_{30})$ alkyl,  $(C_2-C_{30})$ alkenyl, phenyl $(C_1-C_{30})$ alkyl, naphthyl $(C_1-C_{30})$ alkyl, hydroxy $(C_1-C_{30})$ alkyl, hydroxy $(C_2-C_{30})$ alkenyl, hydroxyphenyl $(C_1-C_{30})$ alkyl or hydroxynaphthyl $(C_1-C_{30})$ alkyl; e is, independently for each occurrence, an integer from 1 to 4 inclusive; m is, independently for each occurrence, an integer from 5 to 24 inclusive; n is, independently for each occurrence, an integer from 1 to 5, inclusive; each of  $R^{10}$  and  $R^{11}$  is, independently for each occurrence, H,  $(C_1-C_{30})$ alkyl,  $(C_1-C_{30})$ acyl,  $(C_1-C_{30})$ alkylsulfonyl,  $-C((NH)(NH_2))$  or

$$-C(O)-CH_2-N$$
  $N-(CH_2)_f-CH_3$  ; and

 $R^{12}$  and  $R^{13}$  each is, independently for each occurrence,  $(C_1\text{-}C_{30})$  alkyl; provided that:

when  $A^7$  is Ura, Paa or Pta, then  $R^2$  and  $R^3$  are deleted; when  $R^{10}$  is  $(C_1-C_{30})$ acyl,  $(C_1-C_{30})$ alkylsulfonyl,  $-C((NH)(NH_2))$  or

Serial No.:

Filed

Page : 6 of 28

-C(O)-CH<sub>2</sub>-N-(CH<sub>2</sub>)<sub>1</sub>-CH<sub>3</sub>, then 
$$R^{11}$$
 is H or (C<sub>1</sub>-C<sub>30</sub>)alkyl;

- (i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, -37 or -38)NH<sub>2</sub> or hGLP-1(7-36, -37 or -38)OH;
- (ii) a compound of formula (I) is not an analogue of hGLP-1(7-36, -37 or -38)NH<sub>2</sub> or hGLP-1(7-36, -37 or -38)OH wherein a single position has been substituted by Ala;
- (iii) a compound of formula (I) is not  $(Arg^{26,34}, Lys^{38})hGLP-1(7-38)-E$ ,  $(Lys^{26}(N_{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ ,  $(Lys^{34}(N_{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ ,  $(Lys^{26,34}-bis(N_{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ ,  $(Arg^{26}, Lys^{34}(N_{\epsilon}-alkanoyl))hGLP-1(8-36, -37 \text{ or } -38)-E$ ,  $(Arg^{26,34}, Lys^{36}(N_{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$  or  $(Arg^{26,34}, Lys^{36}(N_{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$  or  $(Arg^{26,34}, Lys^{38}(N_{\epsilon}-alkanoyl))hGLP-1(7-38)-E$ , wherein E is -OH or -NH<sub>2</sub>;
- (iv) a compound of formula (I) is not  $Z^1$ -hGLP-1(7-36, -37 or -38)-OH,  $Z^1$ -hGLP-1(7-36, -37 or -38)-NH<sub>2</sub>, wherein  $Z^1$  is selected from the group consisting of:
  - (a) (Arg<sup>26</sup>), (Arg<sup>34</sup>), (Arg<sup>26,34</sup>), (Lys<sup>36</sup>), (Arg<sup>26</sup>, Lys<sup>36</sup>), (Arg<sup>34</sup>, Lys<sup>36</sup>), (D-Lys<sup>36</sup>), (Arg<sup>36</sup>), (Arg<sup>26,34</sup>, Lys<sup>36</sup>) or (Arg<sup>26,36</sup>, Lys<sup>34</sup>);
  - (b)  $(Asp^{21});$
  - (c) at least one of (Aib<sup>8</sup>), (D-Ala<sup>8</sup>) and (Asp<sup>9</sup>); and
  - (d) (Tyr<sup>7</sup>), (N-acyl-His<sup>7</sup>), (N-alkyl-His<sup>7</sup>), (N-acyl-D-His<sup>7</sup>) or (N-alkyl-D-His<sup>7</sup>);
- (v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and
- (vi) a compound of formula (I) is not (N-Me-Ala<sup>8</sup>)hGLP-1(8-36 or -37), (Glu<sup>15</sup>)hGLP-1(7-36 or -37), (Asp<sup>21</sup>)hGLP-1(7-36 or -37) or (Phe<sup>31</sup>)hGLP-1(7-36 or -37) or a pharmaceutically acceptable salt thereof.
- 2. (original) A compound according to claim 1, wherein A<sup>11</sup> is Thr; A<sup>13</sup> is Thr; A<sup>15</sup> is Asp; A<sup>17</sup> is Ser; A<sup>18</sup> is Ser; A<sup>21</sup> is Glu; A<sup>23</sup> is Gln or Glu; A<sup>27</sup> is Glu; A<sup>31</sup> is Trp; or a pharmaceutically acceptable salt thereof.

Serial No.:

Filed

Page : 7 of 28

3. (original) A compound according to claim 2, wherein  $A^9$  is Glu, N-Me-Glu or N-Me-Asp;  $A^{12}$  is Phe, Acc or Aic;  $A^{16}$  is Val, Acc or Aib;  $A^{19}$  is Tyr;  $A^{20}$  is Leu, Acc or Cha;  $A^{24}$  is Ala, Aib or Acc;  $A^{25}$  is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>R<sup>11</sup>))-C(O) or HN-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);  $A^{28}$  is Phe;  $A^{29}$  is Ile or Acc;  $A^{30}$  is Ala or Aib;  $A^{32}$  is Leu, Acc or Cha; and  $A^{33}$  is Val or Acc; or a pharmaceutically acceptable salt thereof.

- 4. (original) A compound according to claim 3, wherein  $A^8$  is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;  $A^{10}$  is Gly;  $A^{12}$  is Phe, A6c or A5c;  $A^{16}$  is Val, A6c or A5c;  $A^{20}$  is Leu, A6c, A5c or Cha;  $A^{22}$  is Gly,  $\beta$ -Ala or Aib;  $A^{24}$  is Ala or Aib;  $A^{29}$  is Ile, A6c or A5c;  $A^{32}$  is Leu, A6c, A5c or Cha;  $A^{33}$  is Val, A6c or A5c;  $A^{35}$  is Aib,  $\beta$ -Ala, Ado, A6c, A5c or Gly; and  $A^{37}$  is Gly, Aib,  $\beta$ -Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof.
- 5. (original) A compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein  $X^4$  for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; and  $R^1$  is OH or NH<sub>2</sub>.
- 6. (original)A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein  $R^2$  is H and  $R^3$  is  $(C_1-C_{30})$ alkyl,  $(C_2-C_{30})$ alkenyl,  $(C_1-C_{30})$ acyl,  $(C_1-C_{30})$ alkylsulfonyl,

$$HO-(CH_2)_2-N$$
  $N-(CH_2)_2SO_2 HO-(CH_2)_2-N$   $N-CH_2-CO OI$   $N-CH_2-CO N-CH_2-CO N-CH_2-CO N-CH_2-CO N-CH_2-CO N-CH_2-CO-$ 

Serial No. : Filed :

Page : 8 of 28

7. (original) A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein  $R^{10}$  is  $(C_1-C_{30})$ acyl,  $(C_1-C_{30})$ alkylsulfonyl or

-C(O)-CH<sub>2</sub>-N N-(CH<sub>2</sub>)<sub>f</sub>-CH<sub>3</sub>, and 
$$R^{11}$$
 is H.

8. (original) A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein  $R^{10}$  is  $(C_4-C_{20})$ acyl,  $(C_4-C_{20})$ alkylsulfonyl or

9. (original) A compound according to claim 1 wherein said compound is  $((N^{\alpha}-HEPES-His)^{7}, Aib^{8,35})hGLP-1(7-36)NH_{2} (SEQ ID NO:3), \\ ((N^{\alpha}-HEPA-His)^{7}, Aib^{8,35})hGLP-1(7-36)NH_{2} (SEQ ID NO:4), \\ (Aib^{8}, \beta-Ala^{35})hGLP-1(7-36)NH_{2} (SEQ ID NO:5), \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:6), \\ (Aib^{8,35}, Arg^{26}, Lys^{34}(N_{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:7), \\ (Aib^{8,35,37}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:8), \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-decanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:9), \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-dodecanesulfonyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:10), \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_{2} (SEQ ID NO:12), \\ (Aib^{8,35}, Arg^{26,34}, Asp^{36}(1-(4-tetradecyl-piperazine)))hGLP-1(7-36)NH_{2} (SEQ ID NO:13), \\ (Aib^{8,35}, Arg^{26,34}, Asp^{36}(1-tetradecylamino))hGLP-1(7-36)NH_{2} (SEQ ID NO:13), \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or \\ (Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_{\epsilon}-tetradecanoyl), Alab^{37}(N_{\epsilon}-tetradecanoyl), Alab^{37}(N_{\epsilon}-tetradecanoyl), Alab^{37}(N_{\epsilon}-tetradecanoyl), Alab^{37}(N_{\epsilon}-tetr$ 

Serial No.:

Filed

Page : 9 of 28

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sub> $\epsilon$ </sub>-tetradecanoyl))hGLP-1(7-36)-OH (SEQ ID NO:15), or a pharmaceutically acceptable salt thereof.

- 10. (original) A compound according to claim 9 wherein said compound is  $(Aib^8, \beta-Ala^{35})hGLP-1(7-36)NH_2$  (SEQ ID NO:5),  $(Aib^{8,35}, Arg^{26}, Lys^{34}(N_\epsilon-tetradecanoyl))hGLP-1(7-36)NH_2$  (SEQ ID NO:7),  $(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N_\epsilon-tetradecanoyl))hGLP-1(7-38)NH_2$  (SEQ ID NO:8),  $(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_\epsilon-decanoyl))hGLP-1(7-36)NH_2$  (SEQ ID NO:9), or  $(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_\epsilon-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH$  (SEQ ID NO:14), or a pharmaceutically acceptable salt thereof.
- 11. (original) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
- 12. (original) A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 13. (original) A method for treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
  - 14. (original) A method according to claim 13 wherein said disease is Type I diabetes

Serial No.:

Filed

Page : 10 of 28

or Type II diabetes.

(original) A compound according to claim 1 wherein said compound is 15. (Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:71); (β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:72); $((N^{\alpha}-Me-His)^{7}, Aib^{8,35})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:73);  $((N^{\alpha}-Me-His)^{7}, Aib^{8}, \beta-Ala^{35})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:74);  $((N^{\alpha}-Me-His)^{7}, Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH_{2}(SEQ ID NO:75);$  $((N^{\alpha}-Me-His)^{7}, Aib^{8}, Arg^{26,34}, \beta-Ala^{35})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:76); (Aib<sup>8</sup>, A6c<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub>(SEQ ID NO:77); (Aib<sup>8</sup>, A5c<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:78); (Aib<sup>8</sup>, D-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:79); (Aib<sup>8,35</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:16); (Aib<sup>8,35</sup>, A5c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:80); (Aib<sup>8,35</sup>, Glu<sup>23</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:17); (Aib 8,24,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:18); (Aib 8,30,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:81); (Aib 8,25,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:82); (Aib<sup>8,35</sup>, A6c<sup>16,20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:83); (Aib<sup>8,35</sup>, A6c<sup>16,29,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:84);  $(Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH_2$  (SEQ ID NO:85);  $(Aib^{8,35}, A6c^{20})hGLP-1(7-36)NH_2$  (SEQ ID NO:86); (Aib<sup>8,35</sup>, Lys<sup>25</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:87);  $(Aib^{8,24,35}, A6c^{20})hGLP-1(7-36)NH_2$  (SEQ ID NO:88); (Aib<sup>8,35</sup>, A6c<sup>29,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:89); (Aib<sup>8,24,35</sup>, A6c<sup>29,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:90); (Aib<sup>8,35</sup>, A6c<sup>12</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:91);

(Aib<sup>8,35</sup>, Cha<sup>20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:92);

Applicant: Zheng Xin Dong

Serial No. : Filed :

Page : 11 of 28

```
(Aib<sup>8,35</sup>, A6c<sup>33</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:93);
(Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH_2 (SEQ ID NO:85);
(Aib<sup>8</sup>, A6c<sup>16,20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:94);
(Aib<sup>8,35</sup>, \beta-Ala<sup>22</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:95);
(Aib<sup>8,22,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:96);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:19);
(Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:97);
(Aib<sup>8,24,25,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:98);
(Aib<sup>8,24,25,35</sup>, A6c<sup>16,20,32</sup>, Glu<sup>23</sup>,)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:99);
(Aib<sup>8</sup>, A6c<sup>32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:100);
(Aib<sup>8</sup>, A5c<sup>32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:101);
(Aib<sup>8</sup>, Glu<sup>23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:20);
(Aib<sup>8,24</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:102);
53: (Aib<sup>8,30</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:103);
(Aib<sup>8,25</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:104);
(Aib<sup>8</sup>, A6c<sup>16,20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:94);
(Aib<sup>8</sup>, A6c<sup>16,29,32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:105);
(Aib<sup>8</sup>, A6c<sup>20,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:106);
(Aib<sup>8</sup>, A6c<sup>20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:107);
(Aib<sup>8</sup>, Lys<sup>25</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:108);
(Aib<sup>8,24</sup>, A6c<sup>20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:109);
(Aib<sup>8</sup>, A6c<sup>29,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:110);
(Aib<sup>8,24</sup>, A6c<sup>29,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:111);
(Aib<sup>8</sup>, A6c<sup>12</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:112);
(Aib<sup>8</sup>, Cha<sup>20</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:113);
(Aib<sup>8</sup>, A6c<sup>33</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:114);
(Aib<sup>8</sup>, A6c<sup>20,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:106);
(Aib<sup>8</sup>, \beta-Ala<sup>22,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:115);
```

Serial No. : Filed :

Page : 12 of 28

```
(Aib<sup>8,22</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:116);
(Aib<sup>8</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:117);
(Aib<sup>8,24</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:118);
(Aib<sup>8,24</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sub>ε</sub>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:119);
(Aib<sup>8,24,25</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:120);
(Aib<sup>8,24,25</sup>, A6c<sup>16,20,32</sup>, Glu<sup>23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:121);
(Aib<sup>8,35</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:122);
(Aib<sup>8,35</sup>, D-Lys<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:123);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:124);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Lys<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:125);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>,)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:21);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:126);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:127);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:128);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)OH (SEQ ID NO:129);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:130);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:131);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl), D-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO:132);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:133);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, β-Ala<sup>37</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:134);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:135);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl), β-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO:136);
(Aib<sup>8,37</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:137);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ado<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO:138);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ado<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:139);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl), D-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO 140);
(Aib<sup>8,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:141);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>37</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:142);
```

Serial No.: Filed:

Page : 13 of 28

```
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:143);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:144);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:145);
(Aib<sup>8</sup>, Lys<sup>26</sup>(N\varepsilon-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:146);
(Aib<sup>8</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:147);
(Aib<sup>8</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:148);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:149);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:150);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:151);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-decanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:152);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(Nε-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:153);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:154);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:155);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:156);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:157);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:158);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:159);
(Aib<sup>8</sup>, Lys<sup>26</sup>(Nε-octanoyl), Arg<sup>34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:160);
(Aib<sup>8</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), Arg<sup>34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:161);
(Aib<sup>8</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl), Arg<sup>34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:162);
(Aib<sup>8</sup>, Lys<sup>26</sup>(Nε-decanoyl), Arg<sup>34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:163);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:164);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:165);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(N\varepsilon-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:166);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:167);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:168);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:169);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:170);
```

Applicant: Zheng Xin Dong Serial No.:

Filed:

Page : 14 of 28

```
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:171);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:172);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:173);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:174);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:175);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:176);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:177);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:178);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:179);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:180);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:181);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:182);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:183);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:184);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N\varepsilon-octanoyl))hGLP-1(7-38)NH<sub>2</sub>(SEQ ID NO:185);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-decanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:186);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:187);
 (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-hexadecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:188);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N\epsilon-octanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:189);
 (Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-decanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:190);
 (Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:191);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{\epsilon}-hexadecanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:192);
 (Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N_{\epsilon}-octanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:193);
 (Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{\epsilon}-decanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:194);
 (Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-hexadecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:195);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N_{\epsilon}-octanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:189);
 (Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-decanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:190);
 (Aib<sup>8,35,37</sup>, Arg2<sup>5,26,34</sup>, Lys<sup>38</sup>(Nε-tetradecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:191);
```

Applicant: Zheng Xin Dong

Serial No. : Filed :

Page : 15 of 28

```
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-hexadecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:192);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:196);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:197);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:198);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:199);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:200);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:201);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:202);
(Aib<sup>8</sup>, Lys<sup>34</sup>(Nε-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:203);
(Aib<sup>8</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:204);
(Aib<sup>8</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:205);
(Aib<sup>8</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sub>ε</sub>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:206);
(Aib<sup>8</sup>, Glu<sup>23</sup>, Lys<sup>34</sup>(N<sub>ε</sub>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:207);
(Aib^8, Glu^{23}, A6c^{32}, Lys^{34}(N_ε-octanoyl), β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:208);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:209);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:210);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:211);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-decanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:212);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:213);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:214);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:215);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-decanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:216);
(Aib^8, Lys^{25}, Arg^{26}, Lys^{34}(N^ε-octanoyl), β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:217);
(Aib^8, Lys^{25}, Arg^{26}, Lys^{34}(Nε-tetradecanoyl), β-Ala^{35})hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:218);
(Aib^8, Lys^{25}, Arg^{26}, Lys^{34}(N^ε-hexadecanoyl), β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:219);
(Aib^8, β-Ala^{35}, Lys^{36}(N^ε-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:220);
(Aib^8, β-Ala^{35}, Lys^{36}(N^ε-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:221);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:222);
```

Serial No. : Filed :

Page : 16 of 28

```
(Aib<sup>8</sup>, Arg<sup>26</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:223);
(Aib<sup>8</sup>, Arg<sup>26</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:224);
(Aib<sup>8</sup>, Arg<sup>26</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:225);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:226);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:227);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:228);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:229);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:230);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:231);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:232);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:233);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:234);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:235);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:236);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-octanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:237);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:238);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:239);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:240);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:241);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:242);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:243);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:244);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:245);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:246);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:247);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:248);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:249);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:250);
```

Serial No. : Filed :

Page : 17 of 28

```
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:251);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:252);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:253);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:254);
(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(Nε-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:255);
(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:256);
(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:257);
(Aib<sup>8,24,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:258);
(Aib<sup>8,24,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:259);
(Aib<sup>8,24,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:260);
(Aib<sup>8,24,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:261);
(Aib<sup>8,24,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:262);
(Aib<sup>8,24,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:263);
(Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sub>\epsilon</sub>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:264);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>26</sup>(Nε-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:265);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:266);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>26</sup>(Nε-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:267);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>34</sup>(N<sub>\epsilon</sub>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:268);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sub>\epsilon</sub>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:269);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:270);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:271);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:272);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:273);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:274);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>36</sup>(N\epsilon-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:275);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:276);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:277);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:278);
```

Serial No. : Filed :

Page : 18 of 28

(Aib<sup>8,30,35</sup>, Lys<sup>26</sup>(Nε-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:279); (Aib<sup>8,30,35</sup>, Lys<sup>26</sup>(Nε-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:280);  $(Aib^{8,30,35}, Lys^{26}(N_{\epsilon}-hexadecanoyl), Arg^{34})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:281); (Aib<sup>8,30,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:282); (Aib<sup>8,30,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:283); (Aib<sup>8,30,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:284); (Aib<sup>8,30,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N $^{\epsilon}$ -octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:285); (Aib<sup>8,30,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:286); (Aib<sup>8,30,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N $^{\epsilon}$ -hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:287); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:288); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:289); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:290); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:291); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:292); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:293); (Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:294); (Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:295); (Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:296); (Aib<sup>8,24,30,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:297); (Aib<sup>8,24,30,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:298); (Aib<sup>8,24,30,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Nε-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:299);  $((N^{\alpha}-HEPES-His)^{7}, Aib^{35})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:300);  $((N^{\alpha}-HEPES-His)^{7}, \beta-Ala^{35})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:301);  $((N^{\alpha}-HEPES-His)^{7}, Aib^{8}, β-Ala^{35})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:302); ((Nα-HEPA-His)<sup>7</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:303);  $((N^{\alpha}-HEPA-His)^{7}, \beta-Ala^{35})hGLP-1(7-36)NH_{2}$  (SEQ ID NO:304);

Applicant: Zheng Xin Dong

Serial No. : Filed :

Page : 19 of 28

```
((N^{\alpha}-HEPA-His)^{7}, Aib^{8}, \beta-Ala^{35})hGLP-1(7-36)NH_{2} (SEQ ID NO:305);
((Nα-tetradecanoyl-His)<sup>7</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:306);
((N^{\alpha}\text{-tetradecanoyl-His})^7, \beta\text{-Ala}^{35})\text{hGLP-1}(7\text{-}36)\text{NH}_2 (SEQ ID NO:307);
((N^{\alpha}\text{-tetradecanoyl-His})^7, \text{Aib}^{8,35})\text{hGLP-1}(7-36)\text{NH}_2 (SEQ ID NO:308);
((Nα-tetradecanoyl-His)<sup>7</sup>, Aib<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:309);
((Nα-tetradecanoyl-His)<sup>7</sup>, Arg<sup>26,34</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:310);
((N^{\alpha}\text{-tetradecanoyl-His})^7, \text{Arg}^{26,34}, \beta\text{-Ala}^{35})\text{hGLP-1}(7-36)\text{NH}_2 (SEQ ID NO:311);
((N^{\alpha}\text{-tetradecanoyl-His})^{7}, Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH_{2} (SEQ ID NO:312);
((Nα-tetradecanoyl-His)<sup>7</sup>, Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:313);
((N^{\alpha}\text{-tetradecanoyl-His})^{7}, Arg^{25,26,34}, \beta\text{-Ala}^{35})hGLP-1(7-36)NH_{2} (SEQ ID NO:314);
((Nα-tetradecanoyl-His)<sup>7</sup>, Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:315);
((N^{\alpha}-tetradecanoyl-His)^{7}, Aib^{8}, Arg^{25,26,34}, \beta-Ala^{35})hGLP-1(7-36)NH_{2} (SEQ ID NO:316);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-octanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:317);
(Aib^{8,35}, Lys^{26}(N^{\epsilon}-dodecane sulfonyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:318);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(Nε-hexadecanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:319);
(Aib^{8,35}, Arg^{26}, Lys^{34}(N\epsilon-octanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:320);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-dodecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:321);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-hexadecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:322);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N\varepsilon-octanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:323);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-hexadecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:324);
 (Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-decylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:325);
 (Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-dodecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:326);
 (Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-tetradecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:327);
 (Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-hexadecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:328);
 (Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:329);
 (Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:330);
 (Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:331);
 (Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:332);
```

Applicant: Zheng Xin Dong

Serial No. : Filed :

Page : 20 of 28

```
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:333);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:334);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:335);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:336);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:337);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:338);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:339);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:340);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:341);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:342);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:343);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:344);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:345);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:346);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:347);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:348);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:349);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:350);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:351);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:352);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:353);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:354);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:355);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:356);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:357);
 (Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:358);
 (Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:359);
 (Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:360);
```

Serial No.: Filed:

NO:377);

Page : 21 of 28

```
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:361);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:362);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:363);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Glu<sup>36</sup>(1-dodecylamino))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:364);
(Aib<sup>8,35</sup>, Glu<sup>26</sup>(1-dodecylamino), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:365);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Glu<sup>34</sup>(1-dodecylamino))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:366);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Glu<sup>38</sup>(1-dodecylamino))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:367);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:368);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:369);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:370;
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:371);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:372);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:373);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:374);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:375);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:376);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
```

Serial No.:

Filed:

Page : 22 of 28

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:378);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:379);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:380);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N $\varepsilon$ -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:381);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:382);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:383);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:384);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:385);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:386);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:387);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:388);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:389);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N $^{\epsilon}$ -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:390);

(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:391);

Serial No. : Filed :

Page : 23 of 28

(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:392);

(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:393);

(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:394);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:395);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:396);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:397);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:398);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N $^{\epsilon}$ -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:399);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:400);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:401);

(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:402);

(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:403);

(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:404);

(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:405);

Applicant: Zheng Xin Dong Serial No.:

Filed:

Page : 24 of 28

```
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(Nε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ
ID NO:406);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:407);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:408);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ava<sup>37</sup>, Ado<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:409);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>37</sup>, Ava<sup>38</sup>, Ado<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:27);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Aun<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:28);
(Aib<sup>8,17,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:29);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, D-Asp<sup>37</sup>, Ava<sup>38</sup>, Aun<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:30);
(Gly<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:31);
(Ser<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:32);
(Aib<sup>8</sup>, Glu<sup>22,23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:33);
(Gly<sup>8</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:34);
(Aib<sup>8</sup>, Lys<sup>18</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO35);
(Aib<sup>8</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:36);
(Aib<sup>8</sup>, Lys<sup>33</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:37);
(Aib<sup>8</sup>, Lys<sup>18</sup>, Leu<sup>27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:38);
(Aib<sup>8</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:39);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:40);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:41);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:42);
 (Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38,39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:43);
 (Aib<sup>8</sup>, Lys<sup>18,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:44);
 (Aib<sup>8</sup>, Lys<sup>27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:45);
 (Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:46);
 (Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:47);
 (Aib<sup>8</sup>, D-Arg<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:48);
 (Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:49);
```

Serial No.:

Filed

: 25 of 28 Page

```
(Aib<sup>8</sup>, Phe<sup>31</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:50);
(Aib<sup>8,35</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:51);
(Aib<sup>8,35</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:52);
(Aib<sup>8,35</sup>, Nal<sup>28,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:53);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:54);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:55);
(Aib<sup>8,35</sup>, Nal<sup>19,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:56);
(Aib<sup>8,35</sup>, Nal<sup>12,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:57);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:58);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:59);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-dodecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:60);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Ser<sup>37</sup>(O-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:61);
(Aib^{8,27}, β-Ala^{35,37}, Arg^{38}, Lys^{39}(Nε-octanoyl))hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:62);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(Nε-octanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:63);
(Aib^8, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N^ε-decanoyl))hGLP-1(7-37)NH_2 (SEQ ID NO:64);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(Nε-tetradecanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:65);
(Aib^8, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N^ε-dodecanoyl))hGLP-1(7-37)NH_2 (SEQ ID NO:410); or
(Aib^8, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N^ε-dodecanoyl))hGLP-1(8-37)NH_2 (SEQ ID NO:411);
or a pharmaceutically acceptable salt thereof.
```

16. (original) A compound according to claim 15 wherein said compound is (Aib<sup>8,35</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:16); (Aib<sup>8,35</sup>, Glu<sup>23</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:17); (Aib 8,24,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:18); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:19); (Aib<sup>8</sup>, Glu<sup>23</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:20); (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:21); (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:22);

Applicant: Zheng Xin Dong Serial No.:

Page : 26 of 28

Filed

```
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:23);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:24);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(Nε-Aec-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:25);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ava<sup>37</sup>, Ado<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:26);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>37</sup>, Ava<sup>38</sup>, Ado<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:27);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Aun<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:28);
(Aib<sup>8,17,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:29);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, D-Asp<sup>37</sup>, Ava<sup>38</sup>, Aun<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:30);
(Gly<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:31);
(Ser<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:32);
(Aib<sup>8</sup>, Glu<sup>22,23</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:33);
(Gly<sup>8</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:34);
(Aib<sup>8</sup>, Lys<sup>18</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO: 35);
(Aib<sup>8</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:36);
(Aib<sup>8</sup>, Lys<sup>33</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:37);
 (Aib<sup>8</sup>, Lys<sup>18</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:38);
 (Aib<sup>8</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:39);
 (Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:40);
 (Aib<sup>8,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:41);
 (Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:42);
 (Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38,39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:43);
 (Aib<sup>8</sup>, Lys<sup>18,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:44);
 (Aib<sup>8</sup>, Lys<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:45);
 (Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:46);
 (Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:47);
 (Aib<sup>8</sup>, D-Arg<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:48);
 (Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:49);
 (Aib<sup>8</sup>, Phe<sup>31</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:50);
```

Serial No.:

Filed

Page : 27 of 28

```
(Aib<sup>8,35</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:51);
(Aib<sup>8,35</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:52);
(Aib<sup>8,35</sup>, Nal<sup>28,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:53);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:54);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:55);
(Aib<sup>8,35</sup>, Nal<sup>19,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:56);
(Aib<sup>8,35</sup>, Nal<sup>12,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:57);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:58);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(Nε-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:59);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Nε-dodecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:60);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Ser<sup>37</sup>(O-decanoyl))hGLP-1(7-37)-NH<sub>2</sub> (SEQ ID NO:61);
(Aib<sup>8,27</sup>, β-Ala<sup>35,37</sup>, Arg<sup>38</sup>, Lys<sup>39</sup>(Nε-octanoyl))hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:62);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(Nε-octanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:63);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>37</sup>(N\epsilon-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:64); or
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(Nε-tetradecanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:65);
or a pharmaceutically acceptable salt thereof.
```

17-18. (cancelled)